REMARKS

The paper copy of the Sequence Listing for the subject application, is by this amendment, added after the last page of the application to replace the Sequence Listing previously filed on September 13, 2001. The substitute Sequence Listing is believed to correct the errors addressed in the Notification to Comply with Requirements for Patent Applications Containing Nucleotide Sequences and/or Amino Acid Sequence Disclosures. No prohibited new matter is believed to have been introduced.

Applicants submit that the amendments made herein to the specification and claims merely add sequence identifiers and correct clerical errors. Thus, this Amendment does not introduce new matter.

Favorable consideration on the merits is respectfully requested.

Respectfully submitted,

BURNS, DOANE, SWECKER & MATHIS, L.L.P.

By_____
Deborah H. Yellin
Registration No. 45,904

P.O. Box 1404
Alexandria, Virginia 22313-1404
(703) 836-6620

Date: December 5, 2002

Attachment to Amendment and Reply

Marked-Up Copy

Page 6, Paragraph Beginning at Line 4

In a preferred version of the first embodiment of the invention X in position 1 is E, X in position 2 is A, X in position 5 is C, X in position 7 is Q, X in position 11 is N, and X in positions 17-25 are -G-P-P-V-S-C-I-K-R (SEQ ID NO: 101), which gives a peptide the sequence which is SEQ. ID. NO. 2. The linear form is obtained through protection of the cysteine side chains by acetamidomethyl groups $CH_3CONHCH_2$-.

Page 10, Paragraph Beginning at Line 13

The fourth embodiment of the invention relates to peptides consisting of 12 [aminoacids] amino acids. The peptides are based on a modification of the sequence consisting of the amino acids in positions 20-31 in human lactoferrin, counted from the N-terminal end, corresponding to SEQ. ID. NO. 46. The sequences for the peptides according to the third embodiment of the inventions are SEQ. ID. NO. 68-99 in the appended sequence listing. In the general sequence, SEQ. ID. NO. 99, Xaa in position 3 is preferably Gln or Ala, Xaa in position 4 is preferably Trp or Leu, Xaa in position 5 is preferably Gln, Lys, Orn, Ala, or Nle, Xaa in position 6 is preferably Arg, Lys or Ala, Xaa in position 7 is preferably Asn, Orn, Ala, or Nle, Xaa in position 8 is preferably Met or Leu, and Xaa in position 9 is preferably Arg or Lys. In some cases it may be

advantageous to let this sequence be proceeded by the sequence Thr-Lys or the longer sequence Glu-Ala-Thr-Lys (SEQ ID NO: 102).

Attachment to Amendment and Reply

Marked-Up Claims 57, 58, 59, 61, 62, and 63

57. (Amended) The peptide of claim 54, wherein the peptide further comprises GPPVSCIKR (SEQ ID NO: 101) at the carboxy terminus or a functionally equivalent homolog or analog of the peptide.

58. (Amended) The peptide of claim 54, wherein the peptide further comprises TK or EATK (SEQ ID NO: 102) at the amino terminus of the peptide.

59. (Amended) The peptide of claim 57, wherein the peptide further comprises TK or EATK (SEQ ID NO: 102) at the amino terminus of the peptide.

61. (Amended) The peptide of claim 55, wherein the peptide further comprises GPPVSCIKR (SEQ ID NO: 101) at the carboxy terminus or a functionally equivalent homolog or analog of the peptide.

62. (Amended) The peptide of claim 55, wherein the peptide further comprises TK or EATK (SEQ ID NO: 102) at the amino terminus of the peptide.

63. (Amended) The peptide of claim 61, wherein the peptide further comprises TK or EATK (SEQ ID NO: 102) at the amino terminus of the peptide.